Scemblix
Scemblix ingredients
| Active ingredient | Strength |
|---|---|
| Asciminib Hydrochloride | 20 mg/1, 40 mg/1, 100 mg/1 |
What Scemblix is used for
The FDA lists the approved uses on the official label (below). In the EU, asciminib is approved as Scemblix for:
Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP). Scemblix is indicated for the treatment of adult patients with Ph+ CML-CP with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Scemblix
- Generic name
- Asciminib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Tablet, Film Coated
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA215358
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Asciminib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Scemblix?
Scemblix (Asciminib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Scemblix?
Scemblix contains Asciminib Hydrochloride (20 mg/1, 40 mg/1, 100 mg/1).
Is Scemblix approved in Europe?
The same active substance is approved in the EU as Scemblix.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA